{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin+%28KLH%29&page=2", "query": { "intervention": "keyhole limpet hemocyanin (KLH)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 42, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin+%28KLH%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=keyhole+limpet+hemocyanin+%28KLH%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T08:57:18.344Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00923910", "title": "Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Acute Myelogenous (AML)", "Leukemia, Acute Lymphocytic (ALL)", "Leukemia, Chronic Myelogenous (CML)", "Myelodysplastic Syndrome (MDS)", "Non-Hodgkin's Lymphoma (NHL)" ], "interventions": [ { "name": "WT1 Peptide-Pulsed Dendritic Cells", "type": "DRUG" }, { "name": "Donor Lymphocytes", "type": "DRUG" }, { "name": "IL-4", "type": "DRUG" }, { "name": "KLH", "type": "DRUG" }, { "name": "WT1 Peptides", "type": "DRUG" }, { "name": "Endotoxin", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 10, "start_date": "2008-02-22", "completion_date": "2016-11-15", "has_results": true, "last_update_posted_date": "2017-04-12", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923910" }, { "nct_id": "NCT00020670", "title": "Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "CD 40", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2001-02-20", "completion_date": "2003-07-01", "has_results": false, "last_update_posted_date": "2017-06-20", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020670" }, { "nct_id": "NCT00093522", "title": "Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "autologous tumor cell vaccine", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "St. Luke's Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-19", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 2, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093522" }, { "nct_id": "NCT05163080", "title": "SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Newly Diagnosed Glioblastoma" ], "interventions": [ { "name": "SurVaxM", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MimiVax, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 247, "start_date": "2021-11-18", "completion_date": "2024-08-18", "has_results": false, "last_update_posted_date": "2024-02-26", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 11, "location_summary": "San Francisco, California • Miami, Florida • Louisville, Kentucky + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Summit", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05163080" }, { "nct_id": "NCT00006184", "title": "Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Myeloma Immunoglobulin Idiotype Vaccine", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Doxorubicin hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Fludarabine phosphate", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "GMCSF (granulocyte macrophage colony stimulating factor)", "type": "BIOLOGICAL" }, { "name": "GCSF (granulocyte colony stimulating factor)", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2001-02-08", "completion_date": "2008-01-12", "has_results": true, "last_update_posted_date": "2017-10-20", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006184" }, { "nct_id": "NCT00485563", "title": "A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "EC90 (KLH-FITC)", "type": "BIOLOGICAL" }, { "name": "GPI-0100", "type": "BIOLOGICAL" }, { "name": "EC17 (Folate-FITC)", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Interferon-alpha", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Endocyte", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2007-06", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-03-08", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 3, "location_summary": "Omaha, Nebraska • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00485563" }, { "nct_id": "NCT02754362", "title": "A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Glioma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Poly-ICLC as immune adjuvant", "type": "DRUG" }, { "name": "Keyhole limpet hemocyanin (KLH)", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2016-11", "completion_date": "2019-06", "has_results": false, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02754362" }, { "nct_id": "NCT05845996", "title": "Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous and Subcutaneous Single and Repeated Doses of SAR441344 in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "SAR441344", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Keyhole limpet hemocyanin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 56, "start_date": "2018-11-08", "completion_date": "2020-04-10", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05845996" }, { "nct_id": "NCT00282308", "title": "A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Methylprednisone", "type": "DRUG" }, { "name": "C. albicans", "type": "BIOLOGICAL" }, { "name": "Tetanus toxoid adsorbed booster vaccine", "type": "BIOLOGICAL" }, { "name": "23-valent pneumococcal polysaccharide vaccine", "type": "BIOLOGICAL" }, { "name": "Keyhole limpet hemocyanin", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 103, "start_date": "2006-01-23", "completion_date": "2012-05-28", "has_results": true, "last_update_posted_date": "2017-08-10", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Peoria, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Palm Desert", "state": "California" }, { "city": "Upland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00282308" }, { "nct_id": "NCT00003819", "title": "Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "QS21", "type": "BIOLOGICAL" }, { "name": "TF(c)-KLH conjugate vaccine", "type": "BIOLOGICAL" }, { "name": "Thomsen-Friedenreich antigen", "type": "BIOLOGICAL" }, { "name": "keyhole limpet hemocyanin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 21, "start_date": "1998-06", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2013-03-19", "last_synced_at": "2026-10-10T08:57:18.344Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003819" } ] }